PL EN


Preferences help
enabled [disable] Abstract
Number of results
2016 | 63 | 1 | 161-166
Article title

Multiplex real-time PCR to identify a possible reinfection with different strains of human cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients

Content
Title variants
Languages of publication
EN
Abstracts
EN
Human cytomegalovirus (HCMV) infection remains the leading cause of serious contagious complications after allogeneic hematopoietic stem cell transplantation. These infections in HCMV-seropositive recipients can be due to reactivation or reinfection. Different HCMV strains were identified by determining the genotypes isolated from repeatedly tested patients. The UL55 sequences encoding viral glycoprotein B (gB) have been chosen as the target gene. The region, in which the gB precursor protein is cleaved into two fragments by a cellular endoprotease, is characterized by genetic variability, and based on that HCMV is classified into four major genotypes: gB1, gB2, gB3 and gB4. Multiplex real-time PCR assay enabled both, HCMV gB genotyping, as well as simultaneous quantitative assessment of the detected genotypes. This study was carried out in 30 transplant recipients, from whom 105 isolates of HCMV DNA were genotyped. In 40% of recipients, a mixed infection with two or three genotypes was detected. Genotype gB1 dominated in general, and characteristically for mixed infections, the genotype gB3 or gB4 was always present. Although there were no significant differences in the load for each genotype, in case of multiple infections, the number of copies of gB1 genotype was significantly higher when compared to a single gB1 infection. In patients with mixed genotypes, chronic HCMV infections and graft versus host disease were observed more often, as well as antiviral treatment was less effective. It was assumed that these adverse effects can be related to the presence of gB3 and gB4 genotypes.
Publisher

Year
Volume
63
Issue
1
Pages
161-166
Physical description
Dates
published
2016
received
2015-08-01
revised
2015-11-03
accepted
2015-12-18
(unknown)
2016-02-17
Contributors
  • Jagiellonian University Medical College, Chair of Microbiology, Department of Virology, Kraków, Poland
author
  • Jagiellonian University Medical College, Chair of Microbiology, Department of Virology, Kraków, Poland
author
  • Jagiellonian University Medical College, Chair of Microbiology, Department of Virology, Kraków, Poland
  • Jagiellonian University Medical College, Chair of Hematology, Kraków, Poland
  • Jagiellonian University Medical College, Chair of Microbiology, Department of Virology, Kraków, Poland
References
  • Boeckh M, Nichols WG (2004) The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103: 2003-2008.
  • Fries BC, Chou S, Boeckh M, Torok-Storb B (1994) Frequency distribution of cytomegalovirus envelope glycoprotein genotypes in bone marrow transplant recipients. J Infect Dis 169: 769-774.
  • Humar A, Kumar D, Gilbert C, Boivin G (2003) Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease. J Infect Dis 188: 581-584.
  • Isaacson MK, Compton T (2009) Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol 83: 3891-3903.
  • Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A; Transplantation Society International CMV Consensus Group (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89: 779-795.
  • Linares L, Sanclemente G, Cervera C, Hoyo I, Cofán F, Ricart MJ, Pérez-Villa F, Navasa M, Marcos MA, Antón A, Pumarola T, Moreno A (2011) Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc 43: 2145-2148.
  • Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34: 1094-1097.
  • Ljungman P, Hakki M, Boeckh M (2010) Cytomegalovirus in hematopoietic stem cell transplant recipients. Infect Dis Clin North Am 24: 319-337.
  • Manuel O, Asberg A, Pang X, Rollag H, Emery VC, Preiksaitis JK, Kumar D, Pescovitz MD, Bignamini AA, Hartmann A, Jardine AG, Humar A (2009) Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 49: 1160-1166.
  • Pang X, Humar A, Preiksaitis JK (2008) Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assay. J Clin Microbiol 46: 4004-4010.
  • Pignatelli S, Dal Monte P, Rossini G, Landini MP (2004) Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev Med Virol 14: 383-410.
  • Randolph-Habecker J, Iwata M, Torok-Storb B (2002) Cytomegalovirus mediated myelosuppression. J Clin Virol 25 (Suppl 2): S51-S56.
  • Razonable RR, Humar A; AST Infectious Diseases Community of Practice (2013) Cytomegalovirus in solid organ transplantation. Am J Transplant 13 (Suppl 4): 93-106.
  • Roubalová K, Strunecký O, Zufanová S, Procházka B, Vitek A (2010) Genotyping of viral glycoprotein B (gB) in hematopoietic stem cell transplant recipients with active cytomegalovirus infection: analysis of the impact of gB genotypes on the patients' outcome. Epidemiol Mikrobiol Imunol 59: 92-99.
  • Sowmya P, Dhanya V, Madhavan HN, Therese KL (2007) Comparative efficacy of PCR-based restriction fragment length polymorphism (RFLP) & multiplex PCR for glycoprotein B (gB) genotyping of human cytomegalovirus. Indian J Med Res 126: 122-127.
  • The TH, van den Berg AP, Harmsen MC, van der Bij W, van Son WJ (1995) The cytomegalovirus antigenemia assay: a plea for standardization. Scand J Infect Dis Suppl 99: 25-29.
  • Torok-Storb B, Boeckh M, Hoy C, Leisenring W, Myerson D, Gooley T (1997) Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation. Blood 90: 2097-2102.
  • Vanarsdall AL, Johnson DC (2012) Human cytomegalovirus entry into cells. Curr Opin Virol 2: 37-42.
  • Wada K, Mizuno S, Kato K, Kamiya T, Ozawa K (1997) Cytomegalovirus glycoprotein B sequence variation among Japanese bone marrow transplant recipients. Intervirology 40: 215-219.
  • Wu X, Wang Y, Xu Y, Wu D, Sun A, Zhu Z, Han Y, Qiu H, Tang X, Fu Z, He G, Li C, Ma X, Liu Y (2010) Cytomegalovirus glycoprotein B genotype in hematopoietic stem cell transplant patients from China. Biol Blood Marrow Transplant 16: 647-652. doi. 10.1016/j.bbmt.2009.12.001.
  • Wille PT, Wisner TW, Ryckman B, Johnson DC (2013) Human cytomegalovirus (HCMV) glycoprotein gB promotes virus entry in trans acting as the viral fusion protein rather than as a receptor-binding protein. MBio 4: e00332-13.
  • Xia CS, Zhao XT, Sun YY, Zhang Z (2012) Human cytomegalovirus glycoprotein B genotypes in Chinese hematopoietic stem cell transplant recipients. Intervirology 55: 342-348.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv63p161kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.